2.15 USD
0 (0%)
Overall CELZ gets a fundamental rating of 4 out of 10. We evaluated CELZ against 529 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CELZ is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CELZ had negative earnings in the past year.
CELZ had a negative operating cash flow in the past year.
CELZ had negative earnings in 4 of the past 5 years.
CELZ had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CELZ has a Return On Assets of -81.15%. This is in the lower half of the industry: CELZ underperforms 69.00% of its industry peers.
CELZ has a Return On Equity of -84.45%. This is comparable to the rest of the industry: CELZ outperforms 50.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.15% | ||
| ROE | -84.45% | ||
| ROIC | N/A |
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CELZ's Gross Margin of 60.00% is fine compared to the rest of the industry. CELZ outperforms 78.07% of its industry peers.
CELZ's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CELZ so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
2. Health
2.1 Basic Checks
CELZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CELZ has more shares outstanding
The number of shares outstanding for CELZ has been increased compared to 5 years ago.
There is no outstanding debt for CELZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -2.98, we must say that CELZ is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CELZ (-2.98) is comparable to the rest of the industry.
CELZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.98 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
A Current Ratio of 23.89 indicates that CELZ has no problem at all paying its short term obligations.
CELZ has a better Current ratio (23.89) than 96.98% of its industry peers.
A Quick Ratio of 23.89 indicates that CELZ has no problem at all paying its short term obligations.
CELZ has a Quick ratio of 23.89. This is amongst the best in the industry. CELZ outperforms 96.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 23.89 | ||
| Quick Ratio | 23.89 |
3. Growth
3.1 Past
CELZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.02%, which is quite impressive.
CELZ shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.22%.
CELZ shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.17% yearly.
EPS 1Y (TTM)23.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)22.22%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 27.06% on average over the next years. This is a very strong growth
Based on estimates for the next years, CELZ will show a very strong growth in Revenue. The Revenue will grow by 535.57% on average per year.
EPS Next Y44.19%
EPS Next 2Y27.19%
EPS Next 3Y22%
EPS Next 5Y27.06%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y535.57%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CELZ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELZ. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CELZ's earnings are expected to grow with 22.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.19%
EPS Next 3Y22%
5. Dividend
5.1 Amount
CELZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:CELZ (12/15/2025, 2:04:13 PM)
2.15
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.81%
Inst Owner Change-14.79%
Ins Owners0.49%
Ins Owner Change0%
Market Cap5.55M
Revenue(TTM)11.00K
Net Income(TTM)-5.77M
Analysts82.86
Price Target20.4 (848.84%)
Short Float %1.7%
Short Ratio0.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.59%
Min EPS beat(2)-56.49%
Max EPS beat(2)25.3%
EPS beat(4)2
Avg EPS beat(4)-22.99%
Min EPS beat(4)-74.29%
Max EPS beat(4)25.3%
EPS beat(8)3
Avg EPS beat(8)-12.91%
EPS beat(12)6
Avg EPS beat(12)-54.93%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.81%
EPS NY rev (1m)32.33%
EPS NY rev (3m)32.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 924.5 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.81 | ||
| P/tB | 0.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.91
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS0
BVpS2.65
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.15% | ||
| ROE | -84.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60% | ||
| FCFM | N/A |
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 23.89 | ||
| Quick Ratio | 23.89 | ||
| Altman-Z | -2.98 |
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y44.19%
EPS Next 2Y27.19%
EPS Next 3Y22%
EPS Next 5Y27.06%
Revenue 1Y (TTM)22.22%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y535.57%
EBIT growth 1Y2.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.87%
OCF growth 3YN/A
OCF growth 5YN/A
CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ
What is the ChartMill fundamental rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CELZ.
What is the valuation status of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
ChartMill assigns a valuation rating of 1 / 10 to CREATIVE MEDICAL TECHNOLOGY (CELZ). This can be considered as Overvalued.
How profitable is CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a profitability rating of 1 / 10.
What is the financial health of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
The financial health rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) is 7 / 10.
What is the earnings growth outlook for CREATIVE MEDICAL TECHNOLOGY?
The Earnings per Share (EPS) of CREATIVE MEDICAL TECHNOLOGY (CELZ) is expected to grow by 44.19% in the next year.